Novo Nordisk's Etavopivat Achieves Breakthrough Results in Phase 3 Sickle Cell Disease Trial
核心洞察
Etavopivat demonstrated a 27% reduction in vaso-occlusive crisis (搜索) events and delayed first crisis by approximately 4 months compared to placebo in the HIBISCUS phase 3 trial.
The oral pyruvate kinase-R (搜索) activator achieved superior hemoglobin response, with 48.7% of patients showing >1g/dL increase versus 7.2% on placebo after 24 weeks.
Novo Nordisk plans to submit for regulatory approval in the second half of 2026, potentially offering the first therapy in a new drug class for sickle cell disease (搜索) patients.
Novo Nordisk announced topline results from the HIBISCUS phase 3 trial showing that etavopivat, an oral pyruvate kinase-R (搜索) activator, successfully met both co-primary endpoints in treating sickle cell disease (搜索) (SCD). The once-daily oral therapy demonstrated a 27% reduction in annualized vaso-occlusive crisis (搜索) events and superior hemoglobin response compared to placebo in adults and adolescents with SCD.
Trial Design and Patient Population
The HIBISCUS trial was a randomized, double-blinded, 52-week efficacy and safety study investigating etavopivat 400 mg versus placebo in 385 people aged 12 years or older with SCD. Participants were allowed to receive standard of care treatment throughout the trial, positioning etavopivat as an add-on therapy to existing treatments.
Primary Efficacy Results
Etavopivat demonstrated significant clinical benefits across both co-primary endpoints. The median time to first vaso-occlusive crisis (搜索) was substantially prolonged with etavopivat treatment, extending to 38.4 weeks compared to 20.9 weeks for placebo. This represents approximately a 4-month delay in experiencing the first crisis event.
For hemoglobin response, etavopivat showed superior results with 48.7% of patients achieving a hemoglobin increase greater than 1g/dL at week 24, compared to only 7.2% of patients receiving placebo. This corresponds to an adjusted rate difference of 41.2%. Additionally, exploratory analysis revealed that etavopivat significantly reduced the risk of blood transfusion.
Mechanism of Action and Disease Impact
Etavopivat functions as a small molecule allosteric activator of red blood cell pyruvate kinase isozyme (PKR (搜索)), a key enzyme in glycolysis. In SCD, PKR activation reduces 2,3-diphosphoglycerate levels and increases adenosine triphosphate production. The reduction of 2,3-diphosphoglycerate improves hemoglobin-oxygen affinity, preventing sickle hemoglobin polymerization and subsequent sickling. Increased ATP production helps preserve red blood cell membrane integrity and deformability, improving cell survival.
Safety Profile and Regulatory Status
The trial showed that etavopivat appeared to be well tolerated, with a topline safety profile consistent with previous etavopivat trials. The U.S. Food and Drug Administration has granted etavopivat Fast Track, Rare Pediatric Disease and Orphan Drug designations. The European Commission also granted Orphan Drug designation based on a positive opinion from the Committee for Orphan Medicinal Products of the European Medicines Agency.
Clinical Context and Unmet Need
Sickle cell disease (搜索) affects approximately 8 million people worldwide, with the majority living in low and middle-income countries. In the United States, approximately 100,000 people live with SCD, while Europe has approximately 110,000 patients. The disease is characterized by acute and chronic complications including acute chest syndrome (搜索), stroke (搜索), altered cerebral blood flow, multi-organ damage, and cognitive impairment. Despite recent treatment advances, many patients experience significant pain levels and reduced lifespan by approximately 30 years compared to the general population.
"Sickle cell disease (搜索) severely impacts the lives of millions of people. We are very excited that etavopivat has the potential to be a first and best-in-class therapy and transform the lives of people with sickle cell disease, who currently have limited therapeutic options," said Martin Holst Lange, executive vice president, chief scientific officer and head of Research and Development at Novo Nordisk.
Development Timeline and Next Steps
Novo Nordisk plans to submit for the first regulatory approval of etavopivat in the second half of 2026. The detailed results from the HIBISCUS phase 3 trial will be presented at a scientific conference in 2026. The HIBISCUS clinical development program includes additional studies: HIBISCUS2, a 52-week phase 3b trial enrolling 408 participants, and FLORAL, an open-label extension study for long-term safety data collection.
Etavopivat was acquired as part of Novo Nordisk's 2022 acquisition of Forma Therapeutics, representing the company's expansion beyond its diabetes heritage into serious chronic diseases.